人类微小病毒B19感染在桥本甲状腺炎发生中的作用  

Parvovirus B19 infection in pathogenesis of Hashimoto’s thyroiditis

作　　者：王娟红[1] 黄高昇[1] 张伟平[1] 王頔[1] 王文清[1] 王璐[1] 王哲[1] 胡沛臻[1] 张伟[2] 

机构地区：[1]第四军医大学西京医院病理科,西安710032 [2]第四军医大学唐都医院病理科,西安710032

出　　处：《临床与实验病理学杂志》2006年第4期437-439,443,共4页Chinese Journal of Clinical and Experimental Pathology

基　　金：国家自然科学基金(30470825)

摘　　要：目的探讨人类微小病毒B19感染(parvovirus B19,B19)在桥本甲状腺炎(Hashimoto’s thyroiditis,HT)发生中的作用。方法对32例手术切除的HT患者甲状腺组织及16例甲状腺腺瘤患者腺瘤旁正常甲状腺组织,分别用原位杂交法(ISH)和免疫组化(IHC)SP法检测B19病毒DNA和病毒蛋白的表达。结果B19ISH阳性信号同时来源于甲状腺滤泡上皮细胞和间质浸润的淋巴细胞,而IHC阳性信号大多表达于增生甲状腺滤泡上皮细胞,少数表达于间质浸润的淋巴细胞。在HT中,ISH和IHC阳性率分别为71·9%(23/32)和56·3%(18/32),而腺瘤旁正常甲状腺组织中,阳性率分别为12·5%(2/16)和6·25%(1/16),两者比较差异有统计学意义(ISH:χ2=12·783,P=0·000;IHC:χ2=9·158,P=0·001)。结论HT患者甲状腺组织B19感染率明显高于腺瘤旁正常甲状腺组织,提示HT可能是一种新的B19相关性人类疾病,B19感染在桥本甲状腺炎的发生中可能起重要的作用。Purpose To explore the contribution of parvovirus B19 infection to the pathogenesis of Hashimoto＇s thyroiditis （HT）. Methods Tissue blocks from thyroid of 32 HT patients and 16 normal thyroid tissues from surrounding tissue of surgically removed adenoma were used to detect parvovirus B19 by in situ hybridization （ISH） and immunohistochemistry （IHC） techniques simultaneously in a double blind manner. Results The positive signal of ISH arrived from both thyroid follicle epithelial cells （TFEC） and infiltrating lymphocytes while that of IHC, mostly from TFEC. The detected positive rates of ISH and IHC in HT patients were 71.9% （23/32） and 56. 3% （18/32） , respectively. In the normal control group, the positive rates were 12. 5% （2/16） and 6. 25% （1/16） , respectively. Statistical analysis indicated that the B19 positive rates differed significantly between the patients with HT and the normal controls （ISH,X^2 = 12. 783, P =0. 000; IHC,X^2 = 9. 158, P =0. 001 ）. Conclusions Thyroid from patients with HT have higher infection rates with B19 than control subjects, which indicates that HT is a new B19-associated human disease and B19 may play an important role in the pathogenesis of HT.

关 键 词：桥本甲状腺炎 微小病毒B19 原位杂交 免疫组织化学 

分 类 号：R393.1[医药卫生—基础医学] R581.4